PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34098203-1	2022	AIMS: To evaluate associations between new types of buprenorphine waivers (nurse practitioner and physician assistant (NP/PA); 275-patient limit (MD/DO-275)) and both buprenorphine prescribing and health outcomes.	Buprenorphine	52-65	natriuretic peptide A	Homo sapiens	119-124	
34098203-2	2022	METHODS: Using comprehensive county-level data from California 2010-2018, we modeled quarterly associations between numbers of NP/PA and MD/DO-275 waivers and rates of buprenorphine prescribing, opioid-related deaths, emergency department (ED) visits, and hospitalizations among all counties and separately among metropolitan and nonmetropolitan counties using Poisson regression models with county and quarter fixed effects and adjusting for time-varying covariates.	Buprenorphine	168-181	natriuretic peptide A	Homo sapiens	127-132	
34098203-3	2022	RESULTS: Each additional NP/PA and MD/DO-275 waiver was associated with a 2.6% (95%CI: 1.1-4.1%) and 5.8% (4.1-7.4%) increase in buprenorphine prescribing among nonmetropolitan counties, respectively.	Buprenorphine	129-142	natriuretic peptide A	Homo sapiens	25-30	
34098203-6	2022	CONCLUSIONS: NP/PA waivers were associated with increased buprenorphine prescribing among nonmetropolitan counties and MD/DO-275 waivers were associated with increased buprenorphine prescribing among both metropolitan and nonmetropolitan counties.	Buprenorphine	58-71	natriuretic peptide A	Homo sapiens	13-18	
35435071-1	2022	Nurse practitioner (NP) and physician assistant (PA) prescribing can increase access to buprenorphine treatment for opioid use disorder.	Buprenorphine	88-101	natriuretic peptide A	Homo sapiens	20-22	
35435071-1	2022	Nurse practitioner (NP) and physician assistant (PA) prescribing can increase access to buprenorphine treatment for opioid use disorder.	Buprenorphine	88-101	natriuretic peptide A	Homo sapiens	49-51	
35435071-2	2022	In this cross-sectional study, we used deidentified claims from approximately 90% of U.S. retail pharmacies (2017-2018) to examine the association of state policies with the odds of receiving buprenorphine treatment from an NP/PA versus a physician, overall and stratified by urban/rural status.	Buprenorphine	192-205	natriuretic peptide A	Homo sapiens	224-229	
35435071-4	2022	Policies associated with greater odds of buprenorphine treatment from an NP/PA included full scope of practice (SOP) for NPs, full SOP for PAs, Medicaid pay parity for NPs (reimbursement at 100% of the fee-for-service physician rate), and Medicaid expansion.	Buprenorphine	41-54	natriuretic peptide A	Homo sapiens	73-78	
35435071-5	2022	Although most findings with respect to policies were similar in urban and rural settings, the association of Medicaid expansion with NP/PA buprenorphine treatment was driven by rural counties.	Buprenorphine	139-152	natriuretic peptide A	Homo sapiens	133-138